• K8凯发(中国)

    You are here: Home  >> Services  >> Research Services

    Research Services


    I. Service content:

     

    II. Core benefits:

    •  The onlystable transfection processretroviralEnjoy discounts when repurchasingretroviral vectors
    •  If commercialization of the resultsis required later,retroviral vectorsand cell products can beseamlessly integrated intoGMP-levelproduction servicesultra-low cost ; •  Retroviral vectorscan carrylarge target fragmentsup to 7kb ; •  ForNK cellsthat are difficult to infect withlentivirusesthe transduction efficiencyusingretroviralover 50%,with a viability rate of over 95%; •  A professional technical team providesfull-process technical supportto ensure the smooth progress of the project.



    III. Case Study
     


    IV. Service Cases

    Shenzhen Cell Valley has launched a comprehensive collaboration with Academician Tian Zhigang's team at Enkasai Pharmaceuticals, focusing on CAR-NK drug development projects and assisting in the optimization, development, and production of retroviral vectors to accelerate the development of therapeutic drugs.

    Shenzhen Cell Valley has launched a comprehensive collaboration with Academician Yan Xiyun's team at the Institute of Biophysics, Chinese Academy of Sciences, on retroviral vector preparation, CAR-T cell preparation , and related technology transfer. This collaboration aims to promote the industrialization of high-quality research results, help good products move from research institutes to the market, and create a new business model for CAR-T cell products using domestically produced retroviral vectors.


    About Us
    Scan to follow our latest newsScan to follow our latest news
    Contact Us
    400-800-1266

    Working hours: Monday to Friday, 9:00-18:00

    Contact:Ms. Lai

    Email:laijiaqi@61zoeshop.com

    Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

    Cell Valley Group is a leading CGT infrastructure platform in China. We capitalize on the strategic window opened by Decree No. 818 to bridge the gap between clinical research and commercialization.

    We pioneer the "Hospital to Industry" (H2I) model. Basically, we act as the core partner for hospitals, providing a one-stop solution for new biomedical tech—covering process development, GMP manufacturing, QC, and commercial rollout. Our mission is to push China's CGT sector from pure R&D into a standardized, scalable industry.
     Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software